EFEK PEMBERIAN TERAPI ADJUVAN DEKSAMETASON SUBKONJUNGTIVA TERHADAP KADAR TUMOR NECROSIS FACTOR ALPHA (TNF-α) DAN VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) DI CAIRAN VITREUS PADA PROLIFERATIVE VITREORETINOPATHY GRADE B-C (Studi Eksperimental pada Pasien Rhegmatogenous Retinal Detachment di RSUD Dr. Soetomo)

IFAN ROMADHON LUKMANA, NIM011418016301 (2019) EFEK PEMBERIAN TERAPI ADJUVAN DEKSAMETASON SUBKONJUNGTIVA TERHADAP KADAR TUMOR NECROSIS FACTOR ALPHA (TNF-α) DAN VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) DI CAIRAN VITREUS PADA PROLIFERATIVE VITREORETINOPATHY GRADE B-C (Studi Eksperimental pada Pasien Rhegmatogenous Retinal Detachment di RSUD Dr. Soetomo). Thesis thesis, Universitas Airlangga.

[img] Text (Abstrak)
PPDS.IKM. 04-19 Luk e Abstrak.pdf
Download (194kB)
[img] Text (Fulltext)
PPDS.IKM. 04-19 Luk e.pdf
Restricted to Registered users only until 21 June 2022.
Download (1MB) | Request a copy
Official URL: http://lib.unair.ac.id

Abstract

Introduction and Objective: To determine the effect of subconjunctival dexamethasone as adjuvant therapy in proliferative vitreoretinopathy (PVR) by measuring TNF-α and VEGF level in vitreous Method: Experimental study, 36 patients with PVR grade B-C were randomly divided into two groups, 20 patients in treatment group and 16 patients in control group. Vitreous samples were collected undiluted at the beginning of pars plana vitrectomy. All vitreous samples were immediately frozen at -80º C until assayed. TNF-α and VEGF levels were measured using sandwich ELISA. The collected data was processed using Independent t-test and Mann-Whitney test. Result: The mean TNF-α level in treatment group was 0.71 ± 0.33 pg/ml and in control group was 0.75 ± 0.25 pg/ml. There was no difference in intravitreal TNF- α levels between two groups, p value = 0.697 (p> 0.05). The mean VEGF levels in treatment group was 162.96 ± 302.75 pg/ml and control group was of 33.97 ± 48.57 pg/ml. There was no difference in intravitreal VEGF levels between the two groups, p = 0.566 (p> 0.05). Conclusion: Subconjunctival dexamethasone as a adjuvant therapy does not provide a significant difference of TNF-α and VEGF level in PVR. It might be caused by difference in grade of PVR and RD duration between two group, and dexamethasone doesn’t reach expected effective dose for reducing the levels of cytokine and growth factor in vitreous.

Item Type: Thesis (Thesis)
Additional Information: KKA KK PPDS.IKM. 04-19 Luk e
Uncontrolled Keywords: Dexamethasone, Subonjunctival, TNF-α, VEGF, Proliferative Vitreoretinopathy
Subjects: R Medicine > RE Ophthalmology
Divisions: 01. Fakultas Kedokteran > Ilmu Penyakit Mata
Creators:
CreatorsNIM
IFAN ROMADHON LUKMANA, NIM011418016301NIM011418016301
Contributors:
ContributionNameNIDN / NIDK
Thesis advisorEvelyn Komaratih, Dr., dr., SpM(K)UNSPECIFIED
Thesis advisorSauli Ari Widjaja, dr., SpM(K)UNSPECIFIED
Depositing User: Tatik Poedjijarti
Date Deposited: 21 Jun 2019 03:44
Last Modified: 21 Jun 2019 03:44
URI: http://repository.unair.ac.id/id/eprint/83465
Sosial Share:

Actions (login required)

View Item View Item